Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.273 | Diagnostic and Prognostic Values of Anti-Ceclic Citullinated Peptide Antibodies in Chinese Population with Rheumatoid Arthritis | Prof. Tam Lai-Shan |
| 2009.409 | Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study | Prof Tam Lai-Shan |
| 2011.050 | A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A-623 Administration in Subjects with Systemic Lupus Erythematosus | Professor Tam Lai-Shan |
| 2009.429 | A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Dr. TAM Lai-Shan |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2008.344 | Premature Atherosclerosis in Early Rheumatoid Arthritis | Prof Tam Lai Shan |
| 2008.161 | SERAPHIN-OL: Study with An ERA in Pulmonary Arterial Hypertension to Improve Clinical Outcome (Open Label) – Long-term Single-arm Open-label Extension Study of the SERAPHIN study, to Assess the Safety and Tolerability of ACT-064922 in Patients with Symptomatic Pulmonary Arterial Hypertension | Prof. TAM Lai Shan |
| 2008.160 | SERAPHIN: Study with Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome | Prof Tam Lai Shan |
| 2008.159 | A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007 | Asso. Prof. TAM Lai Shan |
| 2012.559 | A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists | Prof. TAM Lai Shan |
| 2012.558 | An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus | Professor Tam Lai Shan |
| 2012.557 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | Prof. TAM Lai Shan |
| 2008.343 | The Chinese University of Hong Kong Early Arthritis Study | Prof Tam Lai Shan |
| 2012.476 | Alteration in bone density and microstructure in early rheumatoid arthritis and its relationship with bone erosion: A one-year study by HR-pQCT and MRI | Prof. TAM Lai Shan |
| 2014.082 | A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis | Prof. TAM Lai Shan |
| 2007.486 | A Double-blind, Randomized, Placebo-control Trial to Assess the Effects of Hydroxychloroquine on Progression of Carotid Artery Intimal-Medial Thickening in Psoriatic Arthritis | Ms Tam Lai Shan |
| 2008.391 | A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), A Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 | Prof. TAM Lai Shan |
| 2012.200 | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | Prof. TAM Lai Shan |
| 2010.491 | Effect of early intensive treatment in patients with recent-onset rheumatoid arthritis | Prof. TAM Lai Shan |
| 2010.056 | Effect of anti-TNF | Professor TAM LAI SHAN |
| 2012.007 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | Prof. TAM Lai Shan |
| 2013.568 | A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. | Prof. TAM Lai Shan |
| 2014.167 | Exploiting the immunomodulatory and anti-inflammatory role of IL35 to modulate inflammation and autoreactive B cell activation in rheumatoid arthritis | Prof. TAM Lai Shan |
| 2011.483 | Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study | Prof. TAM Lai Shan |
| 2011.378 | A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) | Prof. TAM Lai Shan |
| 2013.470 | A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) | Prof Tam Lai Shan |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2023.306 | Low-dose computed tomography for the detection of structural changes in axial psoriatic arthritis | Prof. TAM Lai Shan |
| 2023.355 | Sex- And Gender-based analysis of the Effectiveness of advanced therapies in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.706 | Effect of Achieving Minimal Disease on the Progression of Subclinical Coronary Atherosclerosis: A Citywide Prospective Cohort Study in Psoriatic Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2023.051 | Discovering new post-translational modification patterns for the early diagnosis of rheumatoid arthritis | Prof. TAM Lai Shan |
| 2021.343 | AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS COHORT (AXIS) a joint ASAS-GRAPPA project |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.317 | Early identification of axial psoriatic arthritis among patients with psoriasis: a screening study using low-dose computed tomography | Prof. TAM Lai Shan |
| 2022.151 | Osteosarcopenia Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and fracture risk in non-osteoporotic patients with immune-mediated inflammatory disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.315 | Axial involvement in patients with Psoriatic Arthritis in Hong Kong – a cross-sectional pilot study |
Prof TAM Lai Shan 譚麗珊 |
| 2023.633 | Defining active and structural lesions in the sacroiliac joint and spine by MRI and their predictive utility in axial psoriatic arthritis -a prospective study | Prof Tam Lai Shan |
| 2021.460 | Profiling of Serum Protein Biomarkers in Psoriatic Arthritis–Associated Disease Activity Assessment and Bone Damage |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.401 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2023.127 | Machine learning models to quantify and predict radiographic joint damage in rheumatoid arthritis |
Prof. TAM Lai Shan Lai Shan TAM |
| 2023.181 | Anti-inflammatory mechanisms of immune-adipose-related Meteorin-like protein (METRNL) in Systemic Lupus Erythematosus | Dr. TAM Lai Shan |
| 2022.686 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with psoriatic arthritis | Prof. TAM Lai Shan |
| 2017.633 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.605 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus | Prof. TAM Lai Shan |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.359 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
Page 62 of 262.